Abiopharma

🔍 Ribeiro Ramiro (Executive)

Company: EyePoint, Inc. (EYPT)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 19,667 shares of Common Stock (Direct)
  Date: 2026-01-03 | Code: M | equity_swap_involved: false | shares_owned_after: 19,667.00 | transaction_form_type: 4
• Sold 6,373 shares of Common Stock at $17.48 per share (Direct)
  Date: 2026-01-03 | Code: F | equity_swap_involved: false | shares_owned_after: 13,294.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 85,700 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-02 | Code: A | equity_swap_involved: false | shares_owned_after: 85,700.00 | transaction_form_type: 4 | Footnotes: F2, F2
• Acquired 171,400 shares of Stock Option (Right to Buy) at $17.48 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | equity_swap_involved: false | shares_owned_after: 171,400.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 19,667 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-03 | Code: M | equity_swap_involved: false | shares_owned_after: 39,333.00 | transaction_form_type: 4 | Footnotes: F4, F4

Footnotes:

• F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.
• F2: The restricted stock units will vest in three ratable annual installments beginning January 2, 2027.
• F3: The option to purchase will vest and become exercisable as follows: 25% at January 2, 2027 and the remainder ratably, on a monthly basis, over the remaining three years.
• F4: The restricted stock units vest in three ratable annual installments beginning January 3, 2026.